Solasia Pharma Advances Oncology Pipeline and Expands Global Reach for Key Cancer Drugs

Solasia Pharma KK ( (JP:4597) ) has provided an update.

Solasia Pharma has provided an update on its oncology and supportive care pipeline alongside its 2025 results, highlighting progress in marketed products and early-stage technology projects. The company is advancing nucleic acid medicine for peritoneal dissemination, RNA editing-based gene therapy, novel antibody modification drug discovery, and fluorescent probe technologies through collaborations with multiple research partners.

In China, Solasia’s antiemetic patch Sancuso has resumed supply following a manufacturing site transfer, with a new licensing deal granting MAAB manufacturing and marketing rights across Greater China and commercial sales slated to start in early 2027. The drug’s competitive positioning was reinforced by Phase III data published in The Oncologist, showing superiority over palonosetron in preventing delayed chemotherapy-induced nausea and vomiting.

For its lymphoma drug DARVIAS, Solasia is expanding global reach via out-licensing, including approvals for sales in Japan, ongoing NDAs in Colombia and Peru, and new commercialization rights in 13 Eastern European countries under a Managed Access Program. The company is also pursuing indication expansions into EBV-positive B-cell lymphoma and breast cancer, supported by recent scientific presentations on efficacy reassessment and mechanism of action, underscoring its strategy to broaden the clinical and commercial footprint of its key oncology asset.

The most recent analyst rating on (JP:4597) stock is a Hold with a Yen29.00 price target. To see the full list of analyst forecasts on Solasia Pharma KK stock, see the JP:4597 Stock Forecast page.

More about Solasia Pharma KK

Solasia Pharma K.K. is a Japan-based specialty pharmaceutical company focused on oncology and supportive care, developing and commercializing treatments for cancer-related conditions such as chemotherapy-induced nausea and vomiting, peripheral T-cell lymphoma, and oral mucositis. The company advances its pipeline through partnerships and out-licensing across China, Japan, South America, Eastern Europe, and other global markets, while also investing in nucleic acid medicines, gene therapy, antibody technologies, and diagnostic probes.

Average Trading Volume: 38,922,743

Technical Sentiment Signal: Sell

Current Market Cap: Yen8.6B

See more data about 4597 stock on TipRanks’ Stock Analysis page.